Patents by Inventor Michael John Witty

Michael John Witty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101916
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 8, 2021
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Patent number: 10882872
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: January 5, 2021
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
  • Patent number: 10562921
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 18, 2020
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
  • Publication number: 20200017531
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 16, 2020
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Patent number: 10420772
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
  • Patent number: 10214495
    Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 26, 2019
    Assignee: University of Cape Town
    Inventors: David Waterson, Michael John Witty, Kelly Chibale, Leslie Street, Diego Gonzalez Cabrera, Tanya Paquet
  • Publication number: 20180280399
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
  • Publication number: 20180194741
    Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Application
    Filed: July 13, 2015
    Publication date: July 12, 2018
    Inventors: DAVID WATERSON, MICHAEL JOHN WITTY, KELLY CHIBALE, LESLIE STREET, DIEGO GONZALEZ CABRERA, TANYA PAQUET
  • Patent number: 10010555
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: July 3, 2018
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
  • Publication number: 20170348315
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
  • Publication number: 20170327519
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 16, 2017
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Patent number: 9266842
    Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: February 23, 2016
    Assignees: MMV MEDICINES FOR MALARIA VENTURE, UNIVERSITY OF CAPE TOWN
    Inventors: Yassir Younis, Kelly Chibale, Michael John Witty, David Waterson
  • Patent number: 9024033
    Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical foimulation for the inhibition of malaria parasite proliferation.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: May 5, 2015
    Assignee: MMV Medicines for Malaria Venture
    Inventors: Michael John Witty, David Hardick
  • Publication number: 20150031682
    Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 29, 2015
    Inventors: Yassir Younis, Kelly Chibale, Michael John Witty, David Waterson
  • Publication number: 20120295905
    Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Application
    Filed: January 17, 2011
    Publication date: November 22, 2012
    Applicant: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Michael John Witty, David Hardick
  • Patent number: 5883080
    Abstract: Antiparasitic avermectin derivatives of formula (I), where the broken line represents an optional bond, R.sup.1 and R.sup.4 are independently H, OH, halo, oximino, or an organic radical, R.sup.2, R.sup.6 and R.sup.7 are organic radicals and R.sup.3 is alpha-oleandrosyl or 4'-(alpha-oleandrosyl)-alpha-oleandrosyl optionally substituted at the 4'- or 4"-position, and R.sup.12 and R.sup.13 are independently H, CN, CONH.sub.2, C.sub.1 -C.sub.8 alkyl or aryl optionally substituted with at least one halo, OH, C.sub.1 -C.sub.8 alkylthio group.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: March 16, 1999
    Assignee: Pfizer Inc.
    Inventors: Christopher James Dutton, Stephen Paul Gibson, Michael John Witty